Cilengitide treatment decreases adhesion to vitronectin and fibronectin and reduces the expression of TGF-β-induced fibronectin genes, as well as the accumulation of mRNAs for fibronectin and collagen type I. However, cilengitide does not inhibit the development of pulmonary fibrosis in vivo [314]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.